More Positive Data on Mavacamten Presented at ACC Meeting

More positive data about the Bristol Myers Squibb experimental drug mavacamten was revealed at last weekend’s American College of Cardiology meeting and simultaneously published in The Lancet.

The data showed improvement in how patients felt taking the drug, as reported and quantified by the patients themselves. The clinical trial participants filled out a questionnaire called the KCCQ, or Kansas City Cardiomyopathy Questionnaire, 6 different times over the 38 weeks that the trial was ongoing.

Analysis of these responses showed that just over a third of patients who took mavacamten reported a substantial improvement in symptoms, though not all participants responded to the drug.  And, it is important to note that the improvements seen by patients returned to baseline once mavacamten was discontinued.

Mavacamten, formerly known as MYK-461, was developed by the San Francisco based company MyoKardia and acquired by Bristol Myers Squibb late last year for $13.1 billion.

You can read more about these results in

American Journal of Managed Care 

Fierce Biotech

Med Page Today

Healio.com

and here is an interview with Dr. Jay Edelberg of Bristol Myers Squibb about mavacamten.

Read more about history of mavacamten and other investigational drugs for HCM by searching the HCMBeat archives on the home page.

DISCLOSURES:  CYNTHIA BURSTEIN WALDMAN OF HCMBEAT SERVED AS A PATIENT ADVISOR ON THE STEERING COMMITTEE OF MYOKARDIA’S EXPLORER TRIAL AND IS CREDITED AS AN AUTHOR OF THE EXPLORER STUDY.  until recently CYNTHIA also SERVED ON MYOKARDIA’S PATIENT ADVISORY BOARD.

Click to access PIIS0140-6736(21)00763-7.pdf

Click to access PIIS0140-6736(21)00763-7.pdf

Click to access PIIS0140-6736(21)00763-7.pdf

Click to access PIIS0140-6736(21)00763-7.pdf

Click to access PIIS0140-6736(21)00763-7.pdf

Click to access PIIS0140-6736(21)00763-7.pdf

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s